iiTV

Interactive investor TV showcases some of the City’s top talent and puts into clear perspective the hottest investment issues.

Tue, 22nd May 2018 - 13:28

A successful outcome from Phase II studies of its grass allergy treatment has got investors excited. Here’s what the company has to say about the possible $2bn drug.

11030

Knowledge